
    UNITED STATES of America, Plaintiff-Appellee v. Michael Sean GOSS, also known as “Killer,” Defendant-Appellant
    No. 16-11591 Summary Calendar
    United States Court of Appeals, Fifth Circuit.
    Filed November 3, 2017
    
      James Wesley Hendrix, Assistant U.S. Attorney, U.S. Attorney’s Office, Northern District of Texas, Dallas, TX, for Plaintiff-Appellee
    Michael Sean Goss, Pro Se
    Before WIENER, DENNIS, and SOUTHWICK, Circuit Judges.
   PER CURIAM:

The attorney appointed to represent Michael Sean Goss has moved for leave to withdraw and has filed a brief in accordance with Anders v. California, 386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967), and United States v. Flores, 632 F.3d 229 (6th Cir. 2011). Goss has filed an untimely response, which we construe as a motion for leave to file an out-of-time response. We GRANT Goss leave to file his untimely response, We have reviewed counsel’s brief and the relevant portions of the record reflected therein, as well as Goss’s response. We agree with counsel’s assessment that the appeal presents no nonfrivo-lous issue for appellate review.

Goss argues that the district court erred in applying the two-level enhancement under U.S.S.G. § 2D1.1(b)(1) for possession of a firearm. “A defendant’s sentence may properly be enhanced under U.S.S.G. § 2D1.1(b)(1) if the possession of a firearm by one of his coconspirators was reasonably foreseeable.” United States v. Hernandez, 457 F.3d 416, 423 (5th Cir. 2006). As stated in the PSR, Goss purchased methamphetamine multiple times from a coconspirator who was known to carry a firearm during drug transactions. This court has held that a coconspirator’s use of a firearm in a drug transaction will ordinarily be foreseeable “because firearms are tools of the trade in drug conspiracies.” Id. (quoting United States v. Dixon, 132 F.3d 192, 202 (5th Cir. 1997)). Thus, Goss has not raised a non-frivolous argument with respect to this enhancement.

Goss also argues that there is insufficient evidence that he “maintained” a premises for the purpose of manufacturing or distributing a controlled substance within the meaning of U.S.S.G. § 2D1.1(b)(12). Though Goss filed a written objection to the application of § 2D1.1(b)(12), he withdrew his objection at sentencing. A defendant’s withdrawal of an objection constitutes the waiver of that objection, and “[wjaived errors are entirely unreviewable.” United States v. Musquiz, 45 F.3d 927, 931 (5th Cir. 1995). Therefore, Goss has failed to present a nonfrivolous issue for appeal with respect to the application of § 2D1.1(b)(12). See United States v. Rico, 864 F.3d 381, 384 (5th Cir. 2017) (withdrawal of written objection to enhancement at sentencing hearing constituted waiver).

Accordingly, counsel’s motion for leave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED. See 5th Cir. R. 42.2. 
      
       Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.
     